Tags

Type your tag names separated by a space and hit enter

An open clinical trial of risperidone monotherapy in young children with autistic disorder.
Psychopharmacol Bull. 1997; 33(1):155-9.PB

Abstract

Autistic disorder (AD) may be associated with dysfunctional behaviors which significantly interfere with a child's functioning. Risperidone has been described as having salutary effects as an adjunctive pharmacotherapy in adult and pediatric patients with AD. The purpose of this 8-week, open-label study was to examine the effectiveness and tolerability of risperidone monotherapy in young patients with AD. Doses of risperidone were to be started at 0.25 mg qhs and were titrated to maximize clinical efficacy. Six patients (ages 5 to 9 years) were enrolled in this protocol, and all completed it. After 8 weeks of treatment, with a mean risperidone dose of 1.1 mg, improvement in symptomatology was demonstrated by reduced scores on both the Children's Psychiatric Rating Scale (p < .005) and the Clinical Global Impressions Scale (p < .001). The most common side effect were weight gain and sedation. This study provides preliminary evidence that risperidone monotherapy may be safe and effective in ameliorating dysfunctional behaviors in children with AD.

Authors+Show Affiliations

Department of Psychiatry and Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

9133768

Citation

Findling, R L., et al. "An Open Clinical Trial of Risperidone Monotherapy in Young Children With Autistic Disorder." Psychopharmacology Bulletin, vol. 33, no. 1, 1997, pp. 155-9.
Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull. 1997;33(1):155-9.
Findling, R. L., Maxwell, K., & Wiznitzer, M. (1997). An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacology Bulletin, 33(1), 155-9.
Findling RL, Maxwell K, Wiznitzer M. An Open Clinical Trial of Risperidone Monotherapy in Young Children With Autistic Disorder. Psychopharmacol Bull. 1997;33(1):155-9. PubMed PMID: 9133768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An open clinical trial of risperidone monotherapy in young children with autistic disorder. AU - Findling,R L, AU - Maxwell,K, AU - Wiznitzer,M, PY - 1997/1/1/pubmed PY - 1997/1/1/medline PY - 1997/1/1/entrez SP - 155 EP - 9 JF - Psychopharmacology bulletin JO - Psychopharmacol Bull VL - 33 IS - 1 N2 - Autistic disorder (AD) may be associated with dysfunctional behaviors which significantly interfere with a child's functioning. Risperidone has been described as having salutary effects as an adjunctive pharmacotherapy in adult and pediatric patients with AD. The purpose of this 8-week, open-label study was to examine the effectiveness and tolerability of risperidone monotherapy in young patients with AD. Doses of risperidone were to be started at 0.25 mg qhs and were titrated to maximize clinical efficacy. Six patients (ages 5 to 9 years) were enrolled in this protocol, and all completed it. After 8 weeks of treatment, with a mean risperidone dose of 1.1 mg, improvement in symptomatology was demonstrated by reduced scores on both the Children's Psychiatric Rating Scale (p < .005) and the Clinical Global Impressions Scale (p < .001). The most common side effect were weight gain and sedation. This study provides preliminary evidence that risperidone monotherapy may be safe and effective in ameliorating dysfunctional behaviors in children with AD. SN - 0048-5764 UR - https://www.unboundmedicine.com/medline/citation/9133768/An_open_clinical_trial_of_risperidone_monotherapy_in_young_children_with_autistic_disorder_ L2 - https://www.lens.org/lens/search?q=citation_id:9133768 DB - PRIME DP - Unbound Medicine ER -